Foundation Fighting Blindness Retinal Degeneration Fund's Form 4 filing
Opus Genetics, Inc. (IRD) · filed May 20, 2026
- Accession no.
- 0002042266-26-000001
- Filed
- May 20, 2026, 7:29 PM ET
- Trade date
- May 18, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $7.39M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Foundation Fighting Blindness Retinal Degeneration FundCIK 0002042266 | Director, Other: See Remarks |
| Foundation Fighting Blindness, Inc.CIK 0002042532 | Director, Other: See Remarks |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Common Stock | SSaleDisposed | −1,700,000 | $4.35 | −$7,395,000 | 3,792,171 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
For purposes of Section 16 of the Exchange Act of 1934, as amended, the Reporting Persons may be deemed a director by deputization of Issuer by virtue of the fact that Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to serve on the board of directors of Issuer and Dr. Graves is the chair of the board of directors of RDF and a member of the board of directors of FFB and Dr. Bennett is a member of the board of directors of RDF.